CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP): 15 pipeline candidates · ~65 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
64.5 months
D/E 0.50 · 0% dilution
Lead: Approved
15 candidates
N/A
0 buys · 23 sells (180d)
A transparent, data-derived signal for CRISPR Therapeutics AGacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.3B
Cash
$423.3M
Quarterly Burn
$108.9M
Runway
64.5 mo
Revenue
$1.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (15 candidates)
| Drug | Phase |
|---|---|
| CASGEVY | Approved |
| CTX110 | Phase 1 |
| CTX112 | Phase 1 |
| CTX131 | Phase 1 |
| CTX211 | Phase 1/Phase 2 |
| CTX213 | Phase 1/Phase 2 |
| CTX310 | Phase 1 |
| CTX320 | Phase 1 |
| CTX321 | Phase 1/Phase 2 |
| CTX340 | Phase 1 |
Showing 10 of 15 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
490
Total value held
$2.97B
| Holder | Shares | Value |
|---|---|---|
| ark investment management llc | 11,313,623 | $538.2M |
| blackrock, inc. | 7,680,073 | $365.3M |
| state street corp | 3,982,500 | $189.4M |
| geode capital management, llc | 2,377,164 | $113.1M |
| vanguard capital management llc | 2,285,086 | $108.7M |
| fmr llc | 1,954,694 | $93.0M |
| amova asset management americas, inc. | 1,853,875 | $88.2M |
| sumitomo mitsui trust group, inc. | 1,853,875 | $88.2M |
| ubs group ag | 1,762,530 | $83.8M |
| susquehanna international group, llp | 1,647,106 | $78.4M |
Showing top 10 of 490 institutional holders of CRISPR Therapeutics AG. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in CRISPR Therapeutics AG's pipeline?
CRISPR Therapeutics AG (CRSP) has 15 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CRISPR Therapeutics AG's lead drug candidate?
CRISPR Therapeutics AG's most advanced tracked candidate is CASGEVY (Approved) for Severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in patients 12 years and older.
What is CRISPR Therapeutics AG's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CRISPR Therapeutics AG has approximately 64.5 months of cash runway.
What is CRISPR Therapeutics AG's market capitalization?
CRISPR Therapeutics AG's market capitalization is approximately $5.3B.
Who is the CEO of CRISPR Therapeutics AG?
Dr. Samarth Kulkarni Ph.D. is the chief executive officer of CRISPR Therapeutics AG (CRSP).
Get the full picture on CRISPR Therapeutics AG
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.